

such articles be returned to the claimant. In addition, on the same day, a consent decree of condemnation and destruction was entered against the *Thorazine hydrochloride tablets* and the *Butazolidin tablets*.

**5645. Beauty for Life Capsules.** (F.D.C. No. 41312. S. Nos. 24-644 M, 75-231 M.)

QUANTITY: 205 75-capsule btls. at El Segundo, Calif.

SHIPPED: 10-16-57, from Roslyn, N.Y., by Helena Rubenstein, Inc.

LABEL IN PART: "Beauty For Life Three Capsules Contain \* \* \* Vitamin A 4000 U.S.P. Units Vitamin D 400 U.S.P. Units Vitamin B<sub>1</sub> \* \* \* 1 mg. Vitamin C \* \* \* 30 mg. Riboflavin \* \* \* 2 mg. Niacin 10 mg. Vitamin B<sub>6</sub> \* \* \* 3 mg. Vitamin B<sub>12</sub> 9 micrograms Folic Acid 0.6 mg. Calcium Pantothenate 6.6 mg. Gelatin 1800 mg. Royal Jelly 30 mg. \* \* \* Recommended Dosage: Three (3) a day."

LIBELED: 1-6-58, S. Dist. Calif,

CHARGE: 502(a)—when shipped, the name "Beauty For Life Capsules" and the labeling of the article contained false and misleading representations that the article was an adequate and effective treatment for restoring abnormal skin, hair, and nails to normal, that it would aid looks and physical well-being, make one look younger, prevent dryness, brittleness, and splitting of nails indefinitely, and would have beneficial effects in treating nervous tension; and 505(a)—the article was a new drug within the meaning of the law, and an application filed pursuant to the law was not effective with respect to the drug.

DISPOSITION: 2-7-58. Default—destruction.

**5646. Royal jelly capsules.** (F.D.C. No. 40974. S. No. 55-060 M.)

QUANTITY: 585 capsules in btls. at Louisville, Ky., in possession of Royal Drugs of Kentucky.

SHIPPED: 10-11-57, from Cambridge, Mass.

LABEL IN PART: "15 Capsules Queen Bee Brand Royal Jelly \* \* \* Distributed by Royal Drugs of Ky. \* \* \* Each capsule contains 50 mg. Royal Jelly \* \* \* Dietary Supplement."

ACCOMPANYING LABELING: Reprints entitled "Royal Jelly, by R. B. Willson."

RESULTS OF INVESTIGATION: The capsules in the bottles were repackaged and relabeled by the consignee from bulk stock which had been shipped as described above. The above-mentioned accompanying labeling had been produced locally from a reprint of an article in the "American Bee Journal."

LIBELED: 12-4-57, W. Dist. Ky.

CHARGE: 502(a)—the labeling accompanying the article, while held for sale, contained false and misleading representations that *royal jelly* would prolong life, produce sexual rejuvenation, cure cerebral neuritis (pains in the head and down the arm), arthritis, diabetes, asthma, failing eyesight, sterility in women, impotency in men, and increase lactation in women; and 505(a)—the article was a new drug within the meaning of the law, and an application filed pursuant to the law was not effective with respect to the article.

DISPOSITION: 3-14-58. Default—destruction.

**DRUGS REQUIRING CERTIFICATE OR RELEASE, FOR WHICH NONE  
HAD BEEN ISSUED****DRUGS FOR VETERINARY USE****5647. Para-Strep Dust. (F.D.C. No. 41571. S. No. 33-893 P.)**

**QUANTITY:** 15 cases, each containing a total of 175 btl., at Frankford, Del.

**SHIPPED:** 4-2-58, from W. Caldwell, N.J., by Rockland Chemical Co., Inc.

**LABEL IN PART:** (Btl.) "Rockland PARA-STREP Dust \* \* \* An Aid in the Treatment of \* \* \* Chronic Respiratory Disease or Air Sac Infection in Chickens \* \* \* Contents equivalent to 25 Grams Dihydrostreptomycin Base and 50 Grams Para-Amino-Benzoic Acid \* \* \* Contents sufficient to treat 1000 chickens."

**LIBELED:** 5-22-58, Dist. Del.

**CHARGE:** 502(1)—when shipped, the article purported to be and was represented as a drug composed in part of dihydrostreptomycin, a derivative of streptomycin, and it was not from a batch with respect to which a certificate or release had been issued in accordance with regulations.

**DISPOSITION:** 10-30-58. Default—destruction.

**5648. Bacitracin ointment (veterinary). (F.D.C. No. 41353. S. No. 78-036 M.)**

**QUANTITY:** 335 boxes, each containing 1 syringe, at Lincoln, Nebr.

**SHIPPED:** 2-21-57, from Inglewood, Calif., by Delta Laboratories.

**LABEL IN PART:** "Mitox Active Ingredients Per Syringe Bacitracin 3200 Units \* \* \* Veterinarians only \* \* \* Control No. 2175 Expiration Date: Feb. '59."

**RESULTS OF INVESTIGATION:** Examination showed that the article contained substantially less bacitracin than the label declared.

**LIBELED:** 1-21-58, Dist. Nebr.

**CHARGE:** 501(c)—the strength of the article, when shipped, differed from that which it purported and was represented to possess, namely, 3200 units per syringe; 502(a)—the label statement "Per Syringe Bacitracin 3200 Units" was false and misleading; and 502(1)—the article contained bacitracin, and it was not from a batch with respect to which a certificate or release had been issued.

**DISPOSITION:** 2-7-58. Consent—destruction.

**DRUGS IN VIOLATION OF PRESCRIPTION LABELING REQUIREMENTS****5649. Various drugs. (F.D.C. No. 41501. S. Nos. 38-913/20 P, 38-922/4 P.)**

**QUANTITY:** 76,000 *antacid tablets* in btl., 14 1,000-tablet btl. of *salicylamide tablets*, 9 ctns., 12 50-tablet btl. each, of *vaginal tablets*, 22 btl. of *Choluthol capsules*, 44 btl. of *Entrin tablets*, 12 1,000-tablet btl., and 68 100-tablet btl. of *Satinol tablets*, 83 50-tablet btl. of *diethylstilbestrol tablets*, 14 100-capsule btl. of *Quad capsules*, 52 100-tablet btl. of *thyroid tablets*, 18 1,000-capsule btl., and 1 500-capsule btl. of *amobarbital sodium capsules*, at San Francisco, Calif., in possession of Mark Kaplanoff.

**SHIPPED:** The *antacid tablets*, *salicylamide tablets*, *Satinol tablets*, *Quad capsules*, and *amobarbital sodium capsules* were shipped from Rensselaer, N.Y., by the Delmar Pharmacal Corp., between 6-25-56 and 1-2-58; the *vaginal tablets* were shipped from Portland, Oreg., by Haack Laboratories, Inc., on 6-28-57; and the *Choluthol capsules*, *Entrin tablets*, *diethylstilbestrol tablets*,